

Synthesis, Characterization and Anti-Inflammatory, Analgesic, and Antimicrobial activities of substituted 4-(4-oxo-2-phenylquinazolin-3(4H)-yl) N-aryl-methylene benzenesulfonamide derivatives

Dhansay Dewangan^{1*}, D. K. Tripathi¹, Tekeshwar Kumar¹,
Kushagra Nagori¹, Vipin Shah², R.Rajavel²

¹ Rungta College of Pharmaceutical Sciences and Research Bhilai, India.

² Department of Pharmaceutical Chemistry, Nandha College of Pharmacy and Research Center, Erode-52 Tamilnadu, India

*Corres.author: danu_drugs@yahoo.com

Abstract: Reaction of anthranilic acid with benzyl chloride in pyridine afforded 2-Phenyl-3,1-Benzoxazine-4-one (**1**), which on condensation reaction with the sulphanilamide in alcoholic KOH solution yield 4-(4-oxo-2-phenylquinazolin-3(4H)-yl) benzenesulfonamide (**2**). When (**2**) was reacted with different aromatic aldehydes in alcoholic KOH solution, different substituted 4-(4-oxo-2-phenylquinazolin-3(4H)-yl) N-aryl-methylene benzenesulfonamide derivatives were obtained (**3**). The structures of the compounds were confirmed by M.P., TLC, IR, ¹H NMR, MASS spectral analysis. All these synthesized compounds shown to have significant analgesic, anti-inflammatory and anti-bacterial activities.

Keywords- Anthranilic acid, Benzyl chloride, Sulphanilamide, Analgesic, Anti-Inflammatory, Anti-Bacterial activities.

Introduction:

Among the wide variety of heterocycles that have been explored for developing pharmaceutically important molecule, quinazolinone derivatives have played a vital role in medicinal chemistry. There are large number of synthetic compounds with quinazolinone nucleus used for antibacterial and antifungal¹⁻⁴, analgesic and anti-inflammatory activities⁵⁻⁸, antihyperglycemic activity⁹, anticonvulsant activity¹⁰⁻¹¹, antitubercular activity¹²⁻¹⁴, anxiolytic and antidopaminergic activity¹⁵, when properly substituted in quinazolinone nucleus. The broad spectrum of therapeutic values of quinazolinone ring system prompted us to synthesize the title compounds and

screen them for pharmacological activities. The sequence of reactions is as shown in **Scheme I**.

The reaction of starting compound, anthranilic acid and benzyl chloride in pyridine afforded the corresponding 2-Phenyl-3,1-Benzoxazine-4-one (**1**). Their IR spectra showed a carbonyl peak in the region 1666-1700 cm⁻¹. The structure was further confirmed by recording ¹H NMR spectra. Condensation reaction of this derivative with sulphanilamide gave the desired 4-(4-oxo-2-phenylquinazolin-3(4H)-yl)benzenesulfonamide (**2**). The assigned structure has been confirmed by the further IR and ¹H NMR spectra. The


substitution reaction of (2) with different aromatic aldehydes in KOH solution furnished substituted 4-(4-oxo-2-phenylquinazolin-3(4H)-yl) N-aryl-methylene benzenesulfonamide derivatives (3a-3j). The characterization data of all the newly synthesized compounds are tabulated in **Table I**. The structures of the above compounds were confirmed by IR, ¹H NMR and mass spectral studies depicted in **Table II**. These compounds were screened for their Anti-Inflammatory Analgesic, Antimicrobial activities.

Results and Discussion:

IR data of compounds clearly shows a strong C=N stretching band around 1540.21 cm⁻¹ and C=O absorption band around 1750.31 cm⁻¹ which indicates ring closure of quinazolinone ring. All final compounds have strong absorption around 3200 cm⁻¹ and around 1590 cm⁻¹ which are evidence for aromatic C-H and aromatic C-C bonds respectively. IR data also confirms the presence of specific functional groups present in final synthesized compounds. ¹H NMR data also confirms the presence of specific functional groups present in final synthesized compounds. The presence

of shift value 4.1, 3.2, and 10.64-11.52 shown the presence of methoxy, hydroxyl group and Schiff base respectively in synthesized compounds. Exhaustive pharmacological studies have been conducted with the quinazolinone derivative. The 2-position and 3-position is an extremely important site of molecular modification, which play a dominant role in determining the pharmacological activities of quinazolinone derivatives. The synthesized compounds were screened *in-vitro* anti-bacterial with *E.Coli*, *P.aeuriginosa*, *S.aureus*, *B.subtilis* which is cause for common cold and cough. Few compounds like compound 3a, 3c, 4g and 4i were shows good antibacterial activity against standard. So the compound contain 3-position with an substituted 2-OH, 3-OCH₃-4-OH, 4-Cl and 3,4,5-(OCH₃)₃ with phenyl ring in 2- position enhance the antimicrobial activity of quinazolinone derivatives. Of the all the compounds 3c and 3g were shown comparatively significant activity. However, still need some more novel approach towards the functional group at the SAR to explore the pharmacological activities.

Scheme 1



| | |
|------------------------------------|--|
| (3a): R = 2-OH | (4f): R = 2-NO ₂ |
| (3b): R = 4-OCH ₃ | (4g): R = 4Cl |
| (3c): R = 3-OCH ₃ -4-OH | (4h): R = 4-CH ₃ |
| (3d): R = 3-NO ₂ | (4i): R = 3,4,5-(OCH ₃) ₃ |
| (3e): R = -H | (4j): R = 4-N-(CH ₃) ₂ |

Table I: Characterization data of Quinazolinone Derivatives:

| Co mp. | R | Mol.formula | M.P.(° c) | Mol. wt. | App. | Rf | Solibility | %yield (w/w) | Chemical name |
|--------|-------------------------------------|---|-----------|----------|--------------|------|------------|--------------|---|
| 3a | 2-OH | C ₂₇ H ₁₉ N ₃ O ₄ S | 163 | 481 | Brown | 0.57 | DMF | 66.666 | 4-(4-oxo-2-phenylquinazolin-3(4 <i>H</i>)-yl)N-(2hydroxy-phenyl)methylene benzenesulfonamide |
| 3b | 4-OCH ₃ | C ₂₈ H ₂₁ N ₃ O ₄ S | 172 | 495 | Brown | 0.53 | DMF | 48.898 | 4-(4-oxo-2-phenylquinazolin-3(4 <i>H</i>)-yl)N-(4 methoxy phenyl)-methylenebenzenesulfonamide |
| 3c | 3-OCH ₃ -4-OH | C ₂₈ H ₂₁ N ₃ O ₅ S | 143 | 511 | Yellow brown | 0.65 | DMF | 67.171 | 4-(4-oxo-2-phenylquinazolin-3(4 <i>H</i>)-yl)N-(3methoxy-4 hydroxy phenyl) -methylene benzenesulfonamide |
| 3d | 3-NO ₂ | C ₂₇ H ₁₈ N ₄ O ₄ S | 163 | 510 | Yellow white | 0.56 | DMF | 46.177 | 4-(4-oxo-2-phenylquinazolin-3(4 <i>H</i>)-yl)N-(3 nitro phenyl)-methylene benzenesulfonamide |
| 3e | H | C ₂₇ H ₁₉ N ₃ O ₃ S | 133 | 465 | Grey | 0.57 | DMF | 54.75 | 4-(4-oxo-2-phenylquinazolin-3(4 <i>H</i>)-yl)N-(phenyl)-methylene benzenesulfonamide |
| 3f | 2-NO ₂ | C ₂₇ H ₁₈ N ₄ O ₄ S | 162 | 510 | Yellow white | 0.63 | DMF | 42.033 | 4-(4-oxo-2-phenylquinazolin-3(4 <i>H</i>)-yl)N-(2 nitro phenyl) -methylene benzenesulfonamide |
| 3g | 4Cl | C ₂₇ H ₁₈ ClN ₃ O ₃ S | 157 | 499 | Brown white | 0.66 | DMF | 67.738 | 4-(4-oxo-2-phenylquinazolin-3(4 <i>H</i>)-yl)N-(4 chloro- phenyl)-methylene benzenesulfonamide |
| 3h | 4-CH ₃ | C ₂₈ H ₂₁ N ₃ O ₃ S | 154 | 479 | Yellow white | 0.55 | DMF | 61.729 | 4-(4-oxo-2-phenylquinazolin-3(4 <i>H</i>)-yl)N-(3-methyl phenyl)-methylene benzenesulfonamide |
| 3i | 3,4,5-(OCH ₃) | C ₃₀ H ₂₅ N ₃ O ₆ S | 153 | 555 | Brown | 0.61 | DMF | 57.455 | 4-(4-oxo-2-phenylquinazolin-3(4 <i>H</i>)-yl)N-(3,4,5-trimethoxy phenyl)-methylene benzenesulfonamide |
| 3j | 4-N-(CH ₃) ₂ | C ₂₉ H ₂₄ N ₄ O ₃ S | 168 | 508 | Grey | 0.67 | DMF | 80.00 | 4-(4-oxo-2-phenylquinazolin-3(4 <i>H</i>)-yl)N-(4 dimethyl amino phenyl)-methylene benzenesulfonamide |

Experimental Section:

Melting points were determined in open capillaries and were uncorrected. Purity of the compounds were checked by TLC. IR spectra (KBr, cm⁻¹) were recorded on Perkins Elmer Infrared-283 FTIR. ¹HNMR (CDCl₃) on a Bruker 300MHz spectrometer using TMS as an internal reference. The mass spectra were recorded on a API 3000 LC-MS.

2- Phenyl-3,-1-Benzoxazine-4-one (1).

A mixture of Anthranilic Acid (0.1 mol) and Benzyl chloride (0.1mol) in pyridine was stirred mechanically for 30 min. The reaction mixture was cooled and poured into crushed ice and the solid mass, which separated out was filtered and washed with water. It is dried and recrystallized from methanol to give crystalline compound.

4-(4-oxo-2-phenylquinazolin-3(4*H*)-yl)benzenesulfonamide (2).

A mixture of 2- Phenyl-3,-1-Benzoxazine-4-one (0.01 mole) and sulphanilamide (0.01) was taken in a 250

ml round bottom flask and add 100 ml of alcoholic KOH solution to the flask. The mixture was refluxed for 9-12 hours. Then the refluxed mixture was poured into crushed ice. The solid mass which was separated out was filtered and washed with water. It is dried and recrystallized from methanol

4-(4-oxo-2-phenylquinazolin-3(4*H*)-yl)N-aryl-methylene benzenesulfonamide 3(a-j).

A mixture of 4-(4-oxo-2-phenylquinazolin-3(4*H*)-yl)benzenesulfonamide (0.01mole) and different aromatic aldehydes (0.01mole) were taken in round bottom flask and added 100 ml of alcoholic KOH to the flask. The mixture was refluxed for 9-12 hours. Then the refluxed mixture was poured into crushed ice. The solid mass which was separated out was filtered and washed with water. It is dried and recrystallized from methanol.

Table II:IR, NMR and Mass Spectra of Quinazolinone Derivatives

| IR (cm ⁻¹) (KBr) | ¹ H NMR δ (ppm) | MS |
|--|--|------------------|
| 3025.45(Aromatic-C-H str), 1700.31(C=O str), 1640.31(C=C str), 983.73(aromatic C-Cstr), 1540.21(C=Nstr), 931.65(C-N str), 3003.27(O-H str). | 7.27-7.74 (12H, Ar-H), 10.23(1H, -NCH-), 3.2(1H, -OH) | 480 ⁺ |
| 3135.45(Aromatic-C-H str), 1750.31(C=O str), 1631.40(C=C str), 965.47(aromatic C-Cstr), 1545.64(C=Nstr), 926.86(C-N str), 1229.66(C-O str of OCH3) | 6.8-7.3(12H, Ar-H), 11.3(1H, -NCH-), 3.6-4.1(3H, -OCH ₃) | 494 ⁺ |
| 3135.45(Aromatic-C-H str), 1820.31(C=O str), 1730.31(C=C str), 1003.73(aromatic C-Cstr), 1710.21(C=Nstr), 971.64(C-N str), 3303.47(O-H str), , 1219.46(C-O str of OCH3) | 6.5-7.8(12H, Ar-H), 10.75(1H, -NCH-), 4.1(1H, -OH), 3.9-4.2(3H, -OCH ₃) | 510 ⁺ |
| 3267.86(Aromatic-C-H str), 1678.53(C=O str), 1576.45(C=C str), 1332.43(aromatic C-Cstr), 1528.21(C=Nstr), 1085.64(C-N str), 1445.64(-NO ₂ str) | 7.1-7.3(12H, Ar-H), 12.76(1H, -NCH-) | 509 ⁺ |
| 3154.67(Aromatic-C-H str), 1699.75(C=O str), 1567.75(C=C str), 1132.43(aromatic C-Cstr), 1540.21(C=Nstr), 985.64(C-N str) | 7.2-7.5(13H, Ar-H), 11.54(1H, -NCH-), | 464 ⁺ |
| 3345.06(Aromatic-C-H str), 1728.53(C=O str), 1654.64(C=C str), 1533.43(aromatic C-Cstr), 1654.21(C=Nstr), 1001.64(C-N str), 1335.64(-NO ₂ str). | 6.9-7.7(12H, Ar-H), 10.64(1H, -NCH-) | 509 ⁺ |
| 3045.06(Aromatic-C-H str), 1553.28(C=O str), 1451.45(C=C str), 1345.43(aromatic C-Cstr), 1623.21(C=Nstr), 1109.64(C-N str), 715.64(-C-Cl str). | 6.8-7.9(12H, Ar-H), 11.76(1H, -NCH-) | 498 ⁺ |
| 3154.67(Aromatic-C-H str), 1699.75(C=O str), 1567.75(C=C str), 1132.43(aromatic C-Cstr), 1540.21(C=Nstr), 985.64(C-N str), 2985.64(ali C-H str) | 7.3-7.8(12H, Ar-H), 10.48(1H, -NCH-), 3.11-4(3H, -CH ₃) | 478 ⁺ |
| 3334.67(Aromatic-C-H str), 1709.75(C=O str), 1677.75(C=C str), 1012.43(aromatic C-Cstr), 1540.21(C=Nstr), 1085.64(C-N str), 1229.66(C-O str of OCH3) | 7.1-7.7(10H, Ar-H), 10.84(1H, -NCH-),3.6-4.5(9H, -(OCH ₃) ₃) | 554 ⁺ |
| 3334.67(Aromatic-C-H str), 1709.75(C=O str), 1677.75(C=C str), 1012.43(aromatic C-Cstr), 1540.21(C=Nstr), 1085.64(C-N str), 1320.91(N-C str), | 7.1-7.8(11H, Ar-H), 10.04(1H, -NCH-),3.76-4.21(6H,-N-(CH ₃) ₂) | 507 ⁺ |

Pharmacological activity:

Acute Toxicity: Animals: Swiss albino mice weighing 20 – 25 gms were used for the study. Animals were fed a standard pellet (Pranav Agro Industries Ltd., Sangli) and water ad libitum and maintained at 24 – 28 °C temperature, 60 – 70% relative humidity and 12 hr day and night cycle. Animals described as fasted were deprived of food for 4 days, but had free access to water.

In-vitro Antibacterial Screening of Synthesized Compounds:

Plate hole diffusion method: The synthesized compounds were tested for their *in vitro* antibacterial activity against the gram-negative bacteria and gram-positive bacteria, by cup-plate method. Chlorotrimazole and Streptomycin were used as standard drug for antibacterial studies. Nutrient Agar (Beef extract 10 gm, Peptone 10 gm, Sodium Chloride 5 gm, Agar 20 gm, purified water 1000ml) was employed as culture media for antibacterial studies. The ingredients were dissolved in water, and adjust the pH to 7.2 to 7.4 by using dilute alkali/dilute acid and autoclave at 120°C for 20 min. 30-35 ml of nutrient agar was transferred to the Petri dish. 1000µg/disc, 500µg/disc, 250µg/dish concentration of the test compounds are prepared & Dimethyl Formamide (DMF) was used as vehicle and Chlorotrimazole and Streptomycin (250µg/ml) was used as standard. Nutrient agar plates were prepared aseptically to get a thickness of 5-6 mm. The plates were allowed to solidify and inverted to prevent condensate falling on the agar surface. The plates were dried at 37 °C just before inoculation. The standard

inoculum is inoculated in the plates prepared earlier aseptically by dipping a sterile swab in the inoculum, removing the excess of inoculum by pressing and rotating the swab firmly against the sides of the culture tube above the level of the liquid and finally streaking the swab all over the surface of 60 after each application. Finally press the swab round the edge of the agar surface. The sterilized discs for the test drugs were placed in the Petri dishes aseptically. Incubate the Petri dish at 37 °C ± 0.2 °C for about 18-24 hrs, after placing them in the refrigerator for one hour to facilitate uniform diffusion. The average zone diameter of the plates were measured and recorded. All compounds synthesized were tested for antibacterial activity against 5 gram + ve & 5 gram (-) ve bacteria.

Analgesic activity:

Test for analgesic activity was performed by Acetic acid induced writhing method using Swiss albino mice (25-35g) of male sex selected by random sampling technique. Diclofenac (5mg/kg) was used as standard drug for comparison. The test compound (Quinazolinone Derivatives) were administered at dose of 5 mg/kg. The inhibition of writhing in mice by synthesized compound will be compared against to the inhibition of writhing by a standard analgesic agent the reaction time was recorded after 10 min of the administration of standard / test compounds. The percent analgesic activity (PAA) was calculated by the following formula:

$$\text{PAA} = 1 - \frac{\text{Treated}}{\text{Control}} \times 100$$

Table No A: Anti-Bacterial Activity of Quinazolinone derivatives using plate hole diffusion method:

| Compound | one of inhibition (mm) | | | |
|----------------------------|------------------------|----------------------|-----------------|-------------------|
| | <i>E. Coli</i> | <i>P.aeuriginosa</i> | <i>S.aureus</i> | <i>B.Subtilis</i> |
| 3a | 21 | 20 | 20 | 22 |
| 3b | 19 | 18 | 17 | 16 |
| 3c | 20 | 21 | 21 | 22 |
| 3d | 18 | 17 | 16 | 16 |
| 3e | 17 | 16 | 17 | 18 |
| 3f | 17 | 16 | 14 | 18 |
| 3g | 22 | 21 | 21 | 20 |
| 3h | 19 | 16 | 18 | 18 |
| 3i | 21 | 22 | 21 | 21 |
| 3j | 17 | 16 | 18 | 17 |
| Streptomycin (250µg/ml) | 23 | 24 | -- | -- |
| Clotrimazole | -- | -- | 23 | 23 |
| DMF(solvent) | -- | -- | -- | -- |

Table No B: Analgesic effect of Quinazolinone derivatives (5 mg/ kg) and standard drug Diclofenac (5 mg/kg) on Acetic acid induced writhing test in Swiss albino male mice.

| Treatment group | Total number of writhes | %Inhibition |
|-------------------|-------------------------|-------------|
| Control (Vehicle) | 70.0 ± 0.3 | -- |
| Standard drug | 23.67 ± 0.7 | 66.67 |
| 3a | 46.3 ± 0.5 | 34.78 |
| 3b | 43.33 ± 0.88 | 38.11 |
| 3c | 37.3 ± 0.4 | 47.46 |
| 3d | 42.16 ± 0.94 | 39.77 |
| 3e | 42.50 ± 0.76 | 39.28 |
| 3f | 40.33 ± 0.80 | 42.38 |
| 3g | 38.16 ± 0.54 | 45.48 |
| 3h | 42.50 ± 0.92 | 39.28 |
| 3i | 41.33 ± 0.71 | 40.95 |
| 3j | 37.16 ± 0.30 | 44.48 |

(n=3,p<0.1) The experimental groups compared with control

Table No C :Anti-inflammatory effect of Quinazolinone derivative on Carrageenan -induced paw edema in rats.(10mg/kg),using indomethacin as standard drug (10mg/kg),

| Treatment group | Edema induced by Carrageenan (mm.) | %Inhibition |
|-------------------|------------------------------------|-------------|
| Control (Vehicle) | 6.41 ± 0.02 | ---- |
| Standard drug | 3.81 ± 0.03 | 40.56 |
| 3a | 2.11 ± 0.03 | 23.292 |
| 3b | 1.82 ± 0.03 | 18.293 |
| 3c | 2.27 ± 0.02 | 30.605 |
| 3g | 3.67 ± 0.03 | 33.073 |
| 3h | 2.92 ± 0.02 | 28.825 |
| 3i | 2.57 ± 0.03 | 25.449 |

(n=4,p<0.1) The experimental groups compared with control.

Anti-inflammatory activity:

The inhibitory activity of synthesized compound on carrageenan induced rat paw edema will be determined according to mercury displacement method by using plethysmograph. 8 groups of adult male albino rats (150-180gm) four animals in each will be orally dosed with synthesized compound one hour before carrageenan challenge, foot paw edema will be induced by sub planter injection of 0.05ml of 1% suspension of carrageenan in saline in to the planter tissue of one hind paw. The equal vol. of saline will be injected serve as a control group. The standard group will receive indomethacin (10mg/kg) s.c. The mercury displacement will be compared with standard for

evaluation of anti-inflammatory activity of synthesized compounds.

Acknowledgement:

The authors would like to express their gratitude and thanks to the Rungta College of Pharmaceutical Sciences and Research Bhilai and Head, Dept. of Pharmaceutical Chemistry, Nandha College of Pharmacy and Research Institute, Erode for necessary facilities for this research work. I would like to thank Micro Therapeutic Research LAB PVT. LTD., Tamilnadu for their immense help in Scanning Mass spectroscopy. I would like to thank IIT, Chennai Tamilnadu for their immense help in Scanning ¹H NMR studies.

References:

- 1 K. Shiva Prasad, L.Shiva Kumar,Int. J. Chem. Tech. Res.,2,2010,1344.
- 2 Sharma S,Srivastava V K, Bioorg. Med. Chem.,2,2003,5293.
- 3 Pandey V K,Tiwari A K, Int. J. Drug Discovery.,1,2009,52.
- 4 Sachin S. Laddha, Satyendra P. Bhatnagar, Int. Electronic Conference Synth. Org. Chem.,13, 2009,1.
- 5 Trivedi A R,Shah V H,Indian J. Chem.,49B, 2010, 802.
- 6 Olayiwola1 G, Obafemi C A, African J. Biotechnol., 6,2007,777.
- 7 Kavitha P N,Saravanan J, Res. J. Pharm. Biol. Chem. Sci.,1,2010,124.
- 8 Reddy C V,Reddy T, E-J. Chem.,5,2008,155.
- 9 THEIVENDREN P S, PALANIRAJAN V K, Int. J. Pharm. Pharm. Sci.,2,2010,118.
- 10 Nanda A K,Ganguli S, Molecules,12, 2007, 2413.
- 11 Ammar Y A, Zahran M A, Molecules,6, 2001, 267.
- 12 Ahmed A. H. Al-Amiery, Yasmien K. Al-Majedy, African J. Pure Appl. Chem., 3, 2009, 218.
- 13 Singh T,Sharma S,Indian J. Chem.,45B,2005, 2558.
- 14 VASHI R T, PATEL S B, E-J. Chem,6,2009,445.
- 15 Saeed A, Shaheen U, J. Chinese Chem. Soc., 57,2010, 82
